Concepedia

Enarodustat, Conversion and Maintenance Therapy for Anemia in Hemodialysis Patients: A Randomized, Placebo-Controlled Phase 2b Trial Followed by Long-Term Trial

Tadao Akizawa, Masaomi Nangaku, Takuhiro Yamaguchi, Masanobu Arai, Ryosuke Koretomo, Kazuo Maeda, Yuya Miyazawa, Hideki Hirakata

˜The œNephron journals/Nephron journals · 2019 · 49 citations · 26 references

DOIFull text

Open access

Abstract

Enarodustat corrected and maintained Hb levels in anemic patients with hemodialysis-dependent CKD. Phase 3 studies of enarodustat are currently ongoing.

References

26

The Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Who Are Receiving Hemodialysis and Epoetin

Anatole Besarab, W. Kline Bolton, Joan C. Egrie et al. · New England Journal of Medicine · 1998 · 1.9K citations · Full text

History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology

Kamyar Kalantar‐Zadeh · American Journal of Nephrology · 2017 · 1.1K citations · Full text

Identification of erythroferrone as an erythroid regulator of iron metabolism

Léon Kautz, Grace Jung, Erika V. Valore et al. · Nature Genetics · 2014 · 1.1K citations · Full text

, , +6

Hypoxia Regulates Vascular Endothelial Growth Factor Gene Expression in Endothelial Cells

Yuxiang Liu, Shanna R. Cox, Toshisuke Morita et al. · Circulation Research · 1995 · 1K citations

Associations between Changes in Hemoglobin and Administered Erythropoiesis-Stimulating Agent and Survival in Hemodialysis Patients

Deborah L. Regidor, Joel D. Kopple, Csaba P. Kövesdy et al. · Journal of the American Society of Nephrology · 2006 · 410 citations

, , +14